Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Director | June 10, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Faeth Therapeutics, Inc.
Report date June 10, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.41 · Expires 2036-06-09 | Direct | 12,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 12,500 · Balance 12,500 F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 13, 2026 00:33 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $11.41 | $0.00 |
DisclosureSEC source: 0001843508-26-000002 · form4-06132026_120635.xml · derivative · entry 1 Holmen Bob · CIK 0001843508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-06-09 F1 · kind: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:30 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001415889-25-014481 · form4-05232025_040503.xml · derivative · entry 1 Holmen Bob · CIK 0001843508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-05-20 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:08 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001415889-24-016696 · form4-06132024_090618.xml · derivative · entry 1 Holmen Bob · CIK 0001843508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2034-06-10 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:44 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 14,550 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-23-042095 · doc4.xml · derivative · entry 2 Holmen Bob · CIK 0001843508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,550 Underlying: Common Stock · 14,550 shares Expires 2033-07-09 F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:44 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 4,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042095 · doc4.xml · nonDerivative · entry 1 Holmen Bob · CIK 0001843508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,598 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 20:15 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 14,550 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001209191-22-036665 · doc4.xml · derivative · entry 2 Holmen Bob · CIK 0001843508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,550 Underlying: Common Stock · 14,550 shares Expires 2032-06-09 F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 20:15 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 4,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036665 · doc4.xml · nonDerivative · entry 1 Holmen Bob · CIK 0001843508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,132 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:40 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008091 · doc4.xml · derivative · entry 1 Holmen Bob · CIK 0001843508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2031-02-02 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the options granted shall vest and become exercisable each month following February 3, 2021, the Vesting Commencement Date, over three years such that the options shall be 100% vested on the third anniversary of the Vesting Commencement Date, subject to the grantee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.